308 completed, 94 terminated, 88 recruiting, 49 active not recruiting. 279 Phase 2, 198 Phase 1, 59 Not applicable, 58 Phase 3, 9 Early Phase 1.
Follow Primary Myelofibrosis: new trials by email Literature Review of Primary Myelofibrosis trials Research Report on Primary Myelofibrosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| WELL-MPN: A Digital Lifestyle App for Patients With MPNs WELL-MPN Digital App - Myeloproliferative Neoplasms (MPNs) | Not applicable | Not yet recruiting | Brigham and Women's Hospital | 75 | 2027-01-01 | 2026-09-29 |
| Oral Tetrahydrouridine-Decitabine in Patients With Advanced Myeloproliferative Neoplasms Oral THU-decitabine - Myelofibrosis, MPN - Accelerated or Blast Phase | Phase 2 | Not yet recruiting | John Mascarenhas | 20 | 2027-01-01 | 2026-10-14 |
| Revumenib in Patients With Myelofibrosis Revumenib, Ruxolitinib, FEDRATINIB - Myelofibrosis, Post-polycythemia Vera Myelofibrosis | Phase 1 / Phase 2 | Not yet recruiting | John Mascarenhas | 32 | 2026-12-01 | 2026-07-29 |
| Comparing Momelotinib and Ruxolitinib in People With Untreated Myelofibrosis and Low Blood Cell Counts Momelotinib, Ruxolitinib - Myelofibrosis, Myelofibrosis (MF) | Phase 4 | Not yet recruiting | SWOG Cancer Research Network | 268 | 2026-11-01 | 2026-09-17 |
| Bomedemstat (IMG-7289) in Combination With Momelotinib in Patients With Myelofibrosis bomedemstat - Myelofibrosis | Phase 2 | Not yet recruiting | United Lincolnshire Hospitals NHS Trust | 40 | 2026-11-01 | 2026-02-20 |
| Flonoltinib Maleate Oral Regimens in Patients With Myelofibrosis Flonoltinib Maleate orally - Myelofibrosis, Myelofibrosis Due to and Following Polycythemia Vera | Phase 2 | Not yet recruiting | Chengdu Zenitar Biomedical Technology Co., Ltd | 105 | 2026-11-01 | 2026-10-16 |
| Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias Pacritinib, Selinexor - Myelofibrosis, Post-polycythemia Vera Myelofibrosis | Phase 2 | Recruiting | John Mascarenhas | 26 | 2026-10-23 | 2026-10-27 |
| An Exploratory Study on the Use of Gecacitinib in Patients With Myeloid Malignancies and Myelofibrosis During the Peri-transplant Period Following Allogeneic Hematopoietic Stem Cell Transplantation gecacitinib Hydrochloride Tablets - Myeloid Neoplasms With Myelofibrosis | Phase 1 / Phase 2 | Not yet recruiting | Ruijin Hospital | 10 | 2026-10-15 | 2026-10-20 |
| Special Stains in Assessment of Bone Marrow Fibrosis Bone Marrow Fibrosis | Not yet recruiting | Assiut University | 60 | 2026-09-26 | 2026-10-01 | |
| Peri-graft Cytokine Profile: Influence of Hematologic Disease and Donor Type Blood sampling - Myelofibrosis, Acute Leukemia | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 96 | 2026-09-15 | 2026-09-04 | |
| A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib Placebo, Elritercept - Myelofibrosis, Anemia | Phase 3 | Recruiting | Takeda | 324 | 2026-09-10 | 2026-10-01 |
| A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant Biospecimen Collection, Electronic Health Record Review, Haploidentical Hematopoietic Cell Transplantation - Accelerated Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia | Phase 1 | Recruiting | City of Hope Medical Center | 46 | 2026-09-09 | 2026-10-23 |
| A Study to Evaluate DMR-001 in Participants With CALR-mutant Myeloproliferative Neoplasms DMR-001, Ruxolitinib - Myeloproliferative Neoplasms (MPNs) | Phase 1 | Recruiting | Damora Therapeutics | 250 | 2026-09-01 | 2026-10-27 |
| Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in Myelofibrosis ropeginterferon alfa- 2b, Ruxolitinib - Myelofibrosis | Phase 1 | Recruiting | University of Utah | 15 | 2026-08-21 | 2026-10-19 |
| Pacritinib Effectiveness in Real-world Settings Not applicable- observational study - Myelofibrosis (MF) | Recruiting | Swedish Orphan Biovitrum | 60 | 2026-08-13 | 2026-10-21 | |
| ENERGIA: Personalized Exercise Program for Fatigue in Patients With Myeloproliferative Neoplasms and Chronic Myeloid Leukemia Participants will take part in a 12-week exercise program that includes aerobic and resistance training, tailored to their individual fitness level and clinical condition. - Myeloproliferative Disease, Polycythemia Vera | Not applicable | Not yet recruiting | Carmen Fava | 25 | 2026-08-01 | 2026-04-09 |
| QT Interval/Corrected QT Interval （QT/QTc） Clinical Study to Evaluate the Cardiac Safety of TQ05105 Tablets in Healthy Participants TQ05105 tablets, Placebo tablets, Moxifloxacin Hydrochloride Tablets - Myelofibrosis | Phase 1 | Active not recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 60 | 2026-07-30 | 2026-08-07 |
| TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT Tacrolimus, Early Tacrolimus Taper Strategy - GVHD, Hematopoietic Cell Transplantation (HCT) | Phase 1 | Recruiting | Stanford University | 50 | 2026-07-21 | 2026-08-17 |
| Study to Evaluate the Effect of Rabeprazole Sodium Enteric-coated Tablets on the Pharmacokinetics of TQ05105 Tablets TQ05105 tablets, Rabeprazole sodium enteric-coated tablets - Myelofibrosis | Phase 1 | Active not recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 17 | 2026-07-20 | 2026-07-27 |
| A Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of TQ05105 Tablets in Subjects With Intermediate/High-risk Myelofibrosis TQ05105 Tablets (Rovadicitinib Tablets) - Myelofibrosis | Phase 2 | Recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 51 | 2026-06-18 | 2026-07-15 |
Showing 20 of 618. Sign in to see all of them.
Myeloproliferative Disorders (278) · Leukemia, Myeloid, Acute (222) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (207) · Myelodysplastic Syndromes (200) · Leukemia, Lymphocytic, Chronic, B-Cell (198) · Multiple Myeloma (181) · Polycythemia Vera (181) · Lymphoma, Non-Hodgkin (176) · Leukemia, Myelomonocytic, Chronic (174) · Thrombocythemia, Essential (170) · Hodgkin Disease (169) · Lymphoma, Follicular (158) · Lymphoma, Mantle-Cell (156) · Burkitt Lymphoma (151)
Hemic and Lymphatic Diseases (618) · Bone Marrow Diseases (605) · Hematologic Diseases (601) · Neoplasms (341) · Myeloproliferative Disorders (340) · Neoplasms by Histologic Type (299) · Hemorrhagic Disorders (283) · Pathological Conditions, Signs and Symptoms (279) · Leukemia, Myeloid (274) · Pathologic Processes (272) · Neoplasms by Site (264) · Disease Attributes (263) · Chronic Disease (259) · Immune System Diseases (247) · Immunoproliferative Disorders (237)
ruxolitinib (102) · Cyclophosphamide (68) · fludarabine phosphate (61) · Tacrolimus (49) · Peripheral Blood Stem Cell Transplantation (46) · Busulfan (45) · Mycophenolic Acid (40) · Whole-Body Irradiation (36) · fludarabine (30) · Antilymphocyte Serum (29) · Methotrexate (29) · Cyclosporine (27) · Melphalan (26) · Filgrastim (21) · 11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (18)
Fred Hutchinson Cancer Center (32) · M.D. Anderson Cancer Center (32) · Novartis Pharmaceuticals (24) · City of Hope Medical Center (23) · Incyte Corporation (23) · National Cancer Institute (NCI) (17) · Case Comprehensive Cancer Center (11) · John Mascarenhas (11) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (10) · Masonic Cancer Center, University of Minnesota (10) · Mayo Clinic (10) · AbbVie (8) · Celgene (8) · Northwestern University (8) · OHSU Knight Cancer Institute (8)
United States (449) · Italy (100) · Germany (75) · France (72) · Canada (63) · United Kingdom (61) · Spain (59) · Australia (54) · Belgium (44) · China (37) · South Korea (36) · Israel (35) · Poland (35) · Hungary (27) · Japan (27)
John Mascarenhas, MD (12) · Ronald Hoffman, MD (7) · Ayalew Tefferi, MD (6) · Ryotaro Nakamura, MD (5) · Jorge Cortes, MD (4) · Ruben A. Mesa, MD (4) · Ryotaro Nakamura (4) · Srdan Verstovsek, MD (4) · Alessandro Rambaldi, MD (3)
PMID 37042865, PMID 39516087, PMID 40535755, PMID 41958363, PMID 42316774, PMID 23911705, PMID 26069290, PMID 28962635, PMID 29217781, PMID 31527168, PMID 32499241, PMID 33275766, PMID 34551507, PMID 37517413, PMID 41758981, PMID 42452788, PMID 42842696, PMID 10204198, PMID 11468154, PMID 15459300, PMID 15466923, PMID 15570084, PMID 17397698, PMID 17562873, PMID 18451242, PMID 18698002, PMID 18997171, PMID 19270260, PMID 19451433, PMID 19706886, PMID 19720904, PMID 19812383, PMID 19841031, PMID 20008298, PMID 20124511, PMID 20424252, PMID 20651074, PMID 20709666, PMID 20709904, PMID 20843246, PMID 21719601, PMID 21742281, PMID 21874061, PMID 22081489, PMID 22157574, PMID 22259028, PMID 22375970, PMID 22375971, PMID 22480131, PMID 22547163
P30CA033572 (13), P01CA108671 (12), 2023 (9), P30CA015083 (8), P30CA068485 (7), 2017 (6), P30CA006973 (6), P30CA043703 (6), 2018 (5), P30CA015704 (5), 2014 (4), 2015 (4), P01CA015396 (4), P30CA016086 (4), P30CA016672 (4)